Generic placeholder image

Recent Patents on Anti-Cancer Drug Discovery

Author(s): Harinder Singh, Priyanka Kriplani*, Sweta Kamboj and Kumar Guarve

DOI: 10.2174/1574892818666230111152024

DownloadDownload PDF Flyer Cite As
Puerarin: An Anticancer and Anti-Inflammatory Agent

Page: [18 - 36] Pages: 19

  • * (Excluding Mailing and Handling)

Abstract

Objectives: Puerarin is a well-known anti-inflammatory agent which has demonstrated its potential to cure numerous ailments. Though many plants are reported in the literature, still their mechanisms are unversed. In this review, numerous mechanisms of puerarin to cure cancer and other inflammatory disorders, pharmacokinetics and adverse events, and boulevards of further research are discussed.

Methods: Organized research was done using ScienceDirect, PubMed, ResearchGate, Google Scholar, Google Patents and ScienceDirect Medline to quest all the available data to date on puerarin. Different keywords used were “puerarin”, “Pueraria tuberosa”, “cancer”, “antiinflammatory”, “cardiovascular”, “IBD”, “pharmacokinetics” etc.

Results: One hundred thirty-six articles and thirteen patents were studied. Puerarin is reported to treat chronic problems like inflammation, sexual dysfunction, cardiovascular diseases and menaces such as colon, stomach, lung and breast cancer by numerous mechanisms, as these ailments do not progress via a single independent pathway.

Conclusion: This article will definitely help budding researchers scrutinize the wealth of information on the therapeutic chattels of puerarin and identify the gaps that have forbidden its application as a potential molecule to cure various ailments.

[1]
Bharti R, Chopra BS, Raut S, Khatri N. Pueraria tuberosa: A review on traditional uses, pharmacology, and phytochemistry. Front Pharmacol 2021; 11(582506): 1-20.
[http://dx.doi.org/10.3389/fphar.2020.582506] [PMID: 33708108]
[2]
Maji AK, Pandit S, Banerji P, Banerjee D. Pueraria tuberosa: A review on its phytochemical and therapeutic potential. Nat Prod Res 2014; 28(23): 2111-27.
[http://dx.doi.org/10.1080/14786419.2014.928291] [PMID: 24980468]
[3]
Ahmad B, Khan S, Liu Y, et al. Molecular mechanisms of anticancer activities of puerarin. Cancer Manag Res 2020; 12: 79-90.
[http://dx.doi.org/10.2147/CMAR.S233567] [PMID: 32021425]
[4]
Amal KM, Subhadip M, Debdulal B. In-vivo immunomodulatory potential of standardized Pueraria tuberosa extract and its isoflavonoids. Int J Pharm Pharm Sci 2014; 6(1): 861-7.
[5]
Shilpashree VK, Raman D, Kuntal D. Evaluation of phytochemical investigation andimmunomodulatory activity of four different plant species of vidari by carbon clearance teston wister rats. Ann Phytomed 2015; 4(1): 94-8.
[6]
He Y, Wu X, Cao Y, et al. Daidzein exerts anti-tumor activity against bladder cancer cells via inhibition of FGFR3 pathway. Neoplasma 2016; 63(4): 523-31.
[http://dx.doi.org/10.4149/neo_2016_405] [PMID: 27268915]
[7]
Adnan M, Jairajpuri DS, Chaddha M, et al. Discovering tuberosin and villosol as potent and selective inhibitors of akt1 for therapeutic targeting of oral squamous cell carcinoma. J Pers Med 2022; 12(7): 1083.
[http://dx.doi.org/10.3390/jpm12071083] [PMID: 35887580]
[8]
Aboushanab SA, Shevyrin VA, Slesarev GP, et al. Antioxidant and cytotoxic activities of kudzu roots and soy molasses against pediatric tumors and phytochemical analysis of isoflavones using HPLC-DAD-ESI-HRMS. Plants 2022; 11(6): 741.
[http://dx.doi.org/10.3390/plants11060741] [PMID: 35336625]
[9]
Theng KB, Korpenwar AN. Pharmacognostic, phytochemical and physicochemical investigation of Pueraria tuberosa (Roxb. xWilld.) DC. Tuber Int J Sci Res 2014; 3(10): 1020-3.
[10]
Mishra RN. The vajikaran (aphrodisiac) formulations in ayurved. Int J Res Pharm Chem 2012; 2(1): 197-207.
[11]
Verma SK, Jain V, Singh DP. Effect of pueraria tuberosa dc. (Indian kudzu) on blood pressure, fibrinolysis and oxidative stress in patients with stage 1 hypertension. Pak J Biol Sci 2012; 15(15): 742-7.
[http://dx.doi.org/10.3923/pjbs.2012.742.747] [PMID: 24171260]
[12]
Vijay DW, Snehal VP, Sanjay JS, Kalpana VW. Medicinal plants used in preparation of polyherbal ayurvedic formulation Chyawanprash. J Med Plants Res 2013; 7(38): 2801-14.
[http://dx.doi.org/10.5897/JMPR11.1608]
[13]
Hsu FL, Liu IM, Kuo DH, Chen WC, Su HC, Cheng JT. Antihyperglycemic effect of puerarin in streptozotocin-induced diabetic rats. J Nat Prod 2003; 66(6): 788-92.
[http://dx.doi.org/10.1021/np0203887] [PMID: 12828463]
[14]
Tripathi YB, Pandey N, Yadav D, Pandey V. Anti-inflammatory effect of Pueraria tuberosa extracts through improvement in activity of red blood cell anti-oxidant enzymes. Ayu 2013; 34(3): 297-301.
[http://dx.doi.org/10.4103/0974-8520.123131] [PMID: 24501527]
[15]
Tallima H, El Ridi R. Arachidonic acid: Physiological roles and potential health benefits - A review. J Adv Res 2018; 11: 33-41.
[http://dx.doi.org/10.1016/j.jare.2017.11.004] [PMID: 30034874]
[16]
Makhafola TJ, Elgorashi EE, McGaw LJ, Awouafack MD, Verschaeve L, Eloff JN. Isolation and characterization of the compounds responsible for the antimutagenic activity of Combretum microphyllum (Combretaceae) leaf extracts. BMC Complement Altern Med 2017; 17(1): 446.
[http://dx.doi.org/10.1186/s12906-017-1935-5] [PMID: 28874162]
[17]
Ishnava KB, Konar PS. In vitro anthelmintic activity and phytochemical characterization of Corallocarpus epigaeus (Rottler) Hook. f. tuber from ethyl acetate extracts. Bull Natl Res Cent 2020; 44(1): 33.
[http://dx.doi.org/10.1186/s42269-020-00286-z]
[18]
Aruna MR, Kumar M, Senbagam D, Balakrishnan S. Investigation on phytochemical and antimicrobial properties of tuber extracts of Pueraria tuberosa linn. J Pure Appl Microbiol 2016; 10(2): 1573-8.
[19]
Srivastava S, Koley TK, Singh SK, Tripathi YB. The tuber extract of Pueraria tuberosa linn. competitively inhibits DPP-IV activity in normoglycemic rats. Int J Pharm Pharm Sci 2015; 7(9): 227-31.
[20]
Chauhan NS, Sharma V, Thakur M, Christine HFSA, Dixit VK. Pueraria tuberosa DC extract improves androgenesis and sexual behavior via FSH LH cascade. Sci World J 2013; 2013: 1-8.
[http://dx.doi.org/10.1155/2013/780659] [PMID: 24489512]
[21]
Wang S, Zhang S, Wang S, Gao P, Dai L. A comprehensive review on Pueraria: Insights on its chemistry and medicinal value. Biomed Pharmacother 2020; 131: 110734.
[http://dx.doi.org/10.1016/j.biopha.2020.110734] [PMID: 32942158]
[22]
Guo CJ, Xie JJ, Hong RH, Pan HS, Zhang FG, Liang YM. Puerarin alleviates streptozotocin (STZ)-induced osteoporosis in rats through suppressing inflammation and apoptosis via HDAC1/HDAC3 signaling. Biomed Pharmacother 2019; 115(1): 108570.
[http://dx.doi.org/10.1016/j.biopha.2019.01.031] [PMID: 31054509]
[23]
Shukla R, Banerjee S, Tripathi YB. Pueraria tuberosa extract inhibits iNOS and IL-6 through suppression of PKC-α and NF-kB pathway in diabetes-induced nephropathy. J Pharm Pharmacol 2018; 70(8): 1102-12.
[http://dx.doi.org/10.1111/jphp.12931] [PMID: 29770444]
[24]
Wang C, Wang W, Jin X, Shen J, Hu W, Jiang T. Puerarin attenuates inflammation and oxidation in mice with collagen antibody-induced arthritis via TLR4/NF-κB signaling. Mol Med Rep 2016; 14(2): 1365-70.
[http://dx.doi.org/10.3892/mmr.2016.5357] [PMID: 27278131]
[25]
Hu W, Yang X, Zhe C, Zhang Q, Sun L, Cao K. Puerarin inhibits iNOS, COX-2 and CRP expression via suppression of NF-κB activation in LPS-induced RAW264.7 macrophage cells. Pharmacol Rep 2011; 63(3): 781-9.
[http://dx.doi.org/10.1016/S1734-1140(11)70590-4] [PMID: 21857089]
[26]
Mahdy HM, Mohamed MR, Emam MA, Karim AM, Abdel-Naim A, Khalifa AE. The anti-apoptotic and anti-inflammatory properties of puerarin attenuate 3-nitropropionic-acid induced neurotoxicity in rats. Can J Physiol Pharmacol 2014; 92(3): 252-8.
[http://dx.doi.org/10.1139/cjpp-2013-0398] [PMID: 24593790]
[27]
Zheng P, Ji G, Ma Z, et al. Therapeutic effect of puerarin on non-alcoholic rat fatty liver by improving leptin signal transduction through JAK2/STAT3 pathways. Am J Chin Med 2009; 37(1): 69-83.
[http://dx.doi.org/10.1142/S0192415X09006692] [PMID: 19222113]
[28]
Adedapo AA, Fagbohun OA, Dawurung C, Oyagbemi AA, Omobowale TO, Yakubu MA. The aqueous tuber extract of Pueraria tuberosa (willd.) d.c. caused cytotoxic effect on ht 29 cell lines with down regulation of nuclear factor-kappa B (NF-κB). J Complement Integr Med 2019; 16(4): 2016-0119.
[http://dx.doi.org/10.1515/jcim-2016-0119] [PMID: 29045235]
[29]
Gan M, Yin X. Puerarin induced in mantle cell lymphoma apoptosis and its possible mechanisms involving multi-signaling pathway. Cell Biochem Biophys 2015; 71(1): 367-73.
[http://dx.doi.org/10.1007/s12013-014-0207-y] [PMID: 25173778]
[30]
Hien TT, Kim HG, Han EH, Kang KW, Jeong HG. Molecular mechanism of suppression of MDR1 by puerarin from Pueraria lobata via NF-κB pathway and cAMP-responsive element transcriptional activity-dependent up-regulation of AMP-activated protein kinase in breast cancer MCF-7/adr cells. Mol Nutr Food Res 2010; 54(7): 918-28.
[http://dx.doi.org/10.1002/mnfr.200900146] [PMID: 20077420]
[31]
Liu X, Zhao W, Wang W, Lin S, Yang L. Puerarin suppresses LPS-induced breast cancer cell migration, invasion and adhesion by blockage NF-κB and Erk pathway. Biomed Pharmacother 2017; 92: 429-36.
[http://dx.doi.org/10.1016/j.biopha.2017.05.102] [PMID: 28558356]
[32]
Liu X, Li S, Li Y, Cheng B, Tan B, Wang G. Puerarin inhibits proliferation and induces apoptosis by upregulation of miR-16 in bladder cancer cell line T24. Oncol Res 2018; 26(8): 1227-34.
[http://dx.doi.org/10.3727/096504018X15178736525106] [PMID: 29422113]
[33]
Zhang H, Zhai Z, Zhou H, et al. Puerarin inhibits oxLDL-induced macrophage activation and foam cell formation in human THP1 macrophage. BioMed Res Int 2015; 2015: 1-8.
[http://dx.doi.org/10.1155/2015/403616] [PMID: 26576421]
[34]
Sakamoto Y, Naka A, Ohara N, Kondo K, Iida K. Daidzein regulates proinflammatory adipokines thereby improving obesity-related inflammation through PPARγ. Mol Nutr Food Res 2014; 58(4): 718-26.
[http://dx.doi.org/10.1002/mnfr.201300482] [PMID: 24343975]
[35]
Berköz M. Krośniak M, Özkan-Yılmaz F, Özlüer-Hunt A. Prophylactic effect of Biochanin A in lipopolysaccharide-stimulated BV2 microglial cells. Immunopharmacol Immunotoxicol 2020; 42(4): 330-9.
[http://dx.doi.org/10.1080/08923973.2020.1769128] [PMID: 32482108]
[36]
Hwang JS, Kang ES, Han SG, et al. Formononetin inhibits lipopolysaccharide-induced release of high mobility group box 1 by upregulating SIRT1 in a PPARδ-dependent manner. PeerJ 2018; 6(6): e4208.
[http://dx.doi.org/10.7717/peerj.4208]
[37]
Luo L, Zhou J, Zhao H, Fan M, Gao W. The anti-inflammatory effects of formononetin and ononin on lipopolysaccharide-induced zebrafish models based on lipidomics and targeted transcriptomics. Metabolomics 2019; 153(12): 1-11.
[http://dx.doi.org/10.1007/s11306-019-1614-2]
[38]
Wu D, Wu K, Zhu Q, et al. Formononetin administration ameliorates dextran sulfate sodium-induced acute colitis by inhibiting NLRP3 inflammasome signaling pathway. Mediat Inflamm 2018; p. 1.
[39]
Sumalatha M, Munikishore R, Rammohan A, et al. Isoorientin, a selective inhibitor of cyclooxygenase-2 (COX-2) from the tubers of Pueraria tuberosa. Nat Prod Commun 2015; 10(10): 1934578X1501001.
[http://dx.doi.org/10.1177/1934578X1501001017] [PMID: 26669106]
[40]
Anilkumar K, Reddy GV, Azad R, et al. Evaluation of anti-inflammatory properties of isoorientin isolated from tubers of Pueraria tuberosa. Oxid Med Cell Longev 2017; 2017: 1-10.
[http://dx.doi.org/10.1155/2017/5498054] [PMID: 28243356]
[41]
Bulugonda RK. kumar KA, Gangappa D, et al. Mangiferin from Pueraria tuberosa reduces inflammation via inactivation of nlrp3 inflammasome. Sci Rep 2017; 7(1): 42683.
[http://dx.doi.org/10.1038/srep42683] [PMID: 28218280]
[42]
Kim KA, Lee IA, Gu W, Hyam SR, Kim DH. β-Sitosterol attenuates high-fat diet-induced intestinal inflammation in mice by inhibiting the binding of lipopolysaccharide to toll-like receptor 4 in the NF-κB pathway. Mol Nutr Food Res 2014; 58(5): 963-72.
[http://dx.doi.org/10.1002/mnfr.201300433] [PMID: 24402767]
[43]
Pengyu S, Ahmad B, Lijuan Z. Natural β-elemene: Advances in targeting cancer through different molecular pathways. North Am J Academic Res 2018; 1(4): 89-115.
[44]
Zhang Z, Lam TN, Zuo Z. Radix Puerariae: An overview of its chemistry, pharmacology, pharmacokinetics, and clinical use. J Clin Pharmacol 2013; 53(8): 787-811.
[http://dx.doi.org/10.1002/jcph.96] [PMID: 23677886]
[45]
Cherdshewasart W, Subtang S, Dahlan W. Major isoflavonoid contents of the phytoestrogen rich-herb Pueraria mirifica in comparison with Pueraria lobata. J Pharm Biomed Anal 2007; 43(2): 428-34.
[http://dx.doi.org/10.1016/j.jpba.2006.07.013] [PMID: 16930918]
[46]
Luo CF, Yuan M, Chen MS, Liu SM, Ji H. Metabolites of puerarin identified by liquid chromatography tandem mass spectrometry: Similar metabolic profiles in liver and intestine of rats. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878(3-4): 363-70.
[http://dx.doi.org/10.1016/j.jchromb.2009.12.002] [PMID: 20006564]
[47]
Wong R, Rabie B. Effect of puerarin on bone formation. Osteoarthritis Cartilage 2007; 15(8): 894-9.
[http://dx.doi.org/10.1016/j.joca.2007.02.009] [PMID: 17379543]
[48]
Pan ZY, Bao ZS, Wu ZM, et al. The myocardial protective effects of puerarin on STZ-induced diabetic rats. Fen Zi Xi Bao Sheng Wu Xue Bao 2009; 42(2): 137-44.
[PMID: 19537197]
[49]
Yao XJ, Yin JA, Xia YF, et al. Puerarin exerts antipyretic effect on lipopolysaccharide-induced fever in rats involving inhibition of pyrogen production from macrophages. J Ethnopharmacol 2012; 141(1): 322-30.
[http://dx.doi.org/10.1016/j.jep.2012.02.038] [PMID: 22401764]
[50]
Lin F, Xie B, Cai F, Wu G. Protective effect of Puerarin on β-amyloid-induced neurotoxicity in rat hippocampal neurons. Arzneimittelforschung 2012; 62(4): 187-93.
[http://dx.doi.org/10.1055/s-0031-1299763] [PMID: 22278629]
[51]
Zhao M, Du YQ, Yuan L, Wang NN. Protective effect of puerarin on acute alcoholic liver injury. Am J Chin Med 2010; 38(2): 241-9.
[http://dx.doi.org/10.1142/S0192415X10007816] [PMID: 20387222]
[52]
Wong KH, Li GQ, Li KM, Razmovski-Naumovski V, Chan K. Kudzu root: Traditional uses and potential medicinal benefits in diabetes and cardiovascular diseases. J Ethnopharmacol 2011; 134(3): 584-607.
[http://dx.doi.org/10.1016/j.jep.2011.02.001] [PMID: 21315814]
[53]
Sage C, Agami R. Immense promises for tiny molecules: Uncovering miRNA functions. Cell Cycle 2006; 5(13): 1415-21.
[http://dx.doi.org/10.4161/cc.5.13.2890] [PMID: 16775415]
[54]
Aruna MR, Kumar DJM, Palani P, Senbagam D, Senthilkumar B. Effects of Pueraria tuberosa linn hydroalcoholic tuber extract on expression of apoptosis associated proteins in HT-29 human colon carcinoma cell line. Int J Curr Microbiol Appl Sci 2018; 7(6): 3863-73.
[http://dx.doi.org/10.20546/ijcmas.2018.706.455]
[55]
Zhang WG, Liu XF, Meng KW, Hu SY. Puerarin inhibits growth and induces apoptosis in SMMC-7721 hepatocellular carcinoma cells. Mol Med Rep 2014; 10(5): 2752-8.
[http://dx.doi.org/10.3892/mmr.2014.2512] [PMID: 25175767]
[56]
Yu Z, Li W. Induction of apoptosis by puerarin in colon cancer HT-29 cells. Cancer Lett 2006; 238(1): 53-60.
[http://dx.doi.org/10.1016/j.canlet.2005.06.022] [PMID: 16055262]
[57]
Lin YJ, Hou YC, Lin CH, et al. Puerariae radix isoflavones and their metabolites inhibit growth and induce apoptosis in breast cancer cells. Biochem Biophys Res Commun 2009; 378(4): 683-8.
[http://dx.doi.org/10.1016/j.bbrc.2008.10.178] [PMID: 19013426]
[58]
Chen T, Chen H, Wang Y, Zhang J. In vitro and in vivo antitumour activities of puerarin 6ʹʹ-O-xyloside on human lung carcinoma A549 cell line via the induction of the mitochondria-mediated apoptosis pathway. Pharm Biol 2016; 54(9): 1793-9.
[http://dx.doi.org/10.3109/13880209.2015.1127980] [PMID: 26730946]
[59]
Tang YH, Zhu HQ, Zhang YC, et al. Apoptosis of NB4 cells induced by flavonoids of puerarin in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18(2): 326-9.
[PMID: 20416161]
[60]
Hu Y, Li X, Lin L, Liang S, Yan J. Puerarin inhibits non-small cell lung cancer cell growth via the induction of apoptosis. Oncol Rep 2018; 39(4): 1731-8.
[http://dx.doi.org/10.3892/or.2018.6234] [PMID: 29393465]
[61]
Görlach A, Dimova EY, Petry A, et al. Reactive oxygen species, nutrition, hypoxia and diseases: Problems solved? Redox Biol 2015; 6: 372-85.
[http://dx.doi.org/10.1016/j.redox.2015.08.016] [PMID: 26339717]
[62]
Jiang K, Chen H, Tang K, et al. Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway. Oncol Lett 2018; 15(1): 167-74.
[PMID: 29375709]
[63]
Kong ANT, Yu R, Chen C, Mandlekar S, Primiano T. Signal transduction events elicited by natural products: Role of MAPK and caspase pathways in homeostatic response and induction of apoptosis. Arch Pharm Res 2000; 23(1): 1-16.
[http://dx.doi.org/10.1007/BF02976458] [PMID: 10728649]
[64]
Zhang WG, Yin XC, Liu XF, et al. Puerarin induces hepatocellular carcinoma cell apoptosis modulated by MAPK signaling pathways in a dose-dependent manner. Anticancer Res 2017; 37(8): 4425-31.
[http://dx.doi.org/10.21873/anticanres.12744] [PMID: 28739736]
[65]
Kang H, Zhang J, Wang B, et al. Puerarin inhibits M2 polarization and metastasis of tumor-associated macrophages from NSCLC xenograft model via inactivating MEK/ERK 1/2 pathway. Int J Oncol 2017; 50(2): 545-54.
[http://dx.doi.org/10.3892/ijo.2017.3841] [PMID: 28101568]
[66]
Hu Y, Liu K, Bo S, et al. Inhibitory effect of puerarin on vascular smooth muscle cells proliferation induced by oxidised low-density lipoprotein via suppressing ERK 1/2 phosphorylation and PCNA expression. Pharmazie 2016; 71(2): 89-93.
[PMID: 27004373]
[67]
Yu C, Li Y, Chen H, Yang S, Xie G. Decreased expression of aromatase in the Ishikawa and RL95-2 cells by the isoflavone, puerarin, is associated with inhibition of c-jun expression and AP-1 activity. Food Chem Toxicol 2008; 46(12): 3671-6.
[http://dx.doi.org/10.1016/j.fct.2008.09.045] [PMID: 18848966]
[68]
Shao HM, Tang YH, Jiang PJ, et al. Inhibitory effect of flavonoids of puerarin on proliferation of different human acute myeloid leukemia cell lines in vitro. Zhongguo Shi Yan Xue Ye Xue Za Zhi 2010; 18(2): 296-9.
[PMID: 20416155]
[69]
Peng XY, Qi ZH, Chen HP. Study on the differentiation and apoptosis of HL-60 cell line induced by Puerarin. Hunan I Ko Ta Hsueh Hsueh Pao 2001; 26(2): 126-8.
[PMID: 12536642]
[70]
Carling D, Clarke PR, Zammit VA, Hardie DG. Purification] and characterization of the AMP-activated protein kinase. Copurification of acetyl-CoA carboxylase kinase and 3-hydroxy-3-methylglutaryl-CoA reductase kinase activities. Eur J Biochem 1989; 186(1-2): 129-36.
[http://dx.doi.org/10.1111/j.1432-1033.1989.tb15186.x] [PMID: 2598924]
[71]
Wang J, Yang ZR, Guo XF, et al. Synergistic effects of puerarin combined with 5-fluorouracil on esophageal cancer. Mol Med Rep 2014; 10(5): 2535-41.
[http://dx.doi.org/10.3892/mmr.2014.2539] [PMID: 25189132]
[72]
Hua F, Li CH, Chen XG, Liu XP. Daidzein exerts anticancer activity towards SKOV3 human ovarian cancer cells by inducing apoptosis and cell cycle arrest, and inhibiting the Raf/MEK/ERK cascade. Int J Mol Med 2018; 41(6): 3485-92.
[http://dx.doi.org/10.3892/ijmm.2018.3531] [PMID: 29512690]
[73]
Zhang J, Liu L, Wang J, Ren B, Zhang L, Li W. Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells. J Ethnopharmacol 2018; 221: 91-9.
[http://dx.doi.org/10.1016/j.jep.2018.04.014] [PMID: 29660466]
[74]
Zhou Q, Zhang W, Li T, et al. Formononetin enhances the tumoricidal effect of everolimus in breast cancer MDA-MB-468 cells by suppressing the mTOR pathway. Evid base Compl Alternative Med 2019; 1-8.
[75]
Zhang Y, Chen C, Zhang J. Effects and significance of formononetin on expression levels of HIF 1α and VEGF in mouse cervical cancer tissue. Oncol Lett 2019; 18(3): 2248-53.
[http://dx.doi.org/10.3892/ol.2019.10567] [PMID: 31452725]
[76]
Yu X, Gao F, Li W, Zhou L, Liu W, Li M. Formononetin inhibits tumor growth by suppression of EGFR-Akt-Mcl-1 axis in non-small cell lung cancer. J Exp Clin Cancer Res 2020; 39(1): 62.
[http://dx.doi.org/10.1186/s13046-020-01566-2] [PMID: 32276600]
[77]
Sharma SH, Rajamanickam V, Nagarajan S. Antiproliferative effect of p-Coumaric acid targets UPR activation by downregulating Grp78 in colon cancer. Chem Biol Interact 2018; 291: 16-28.
[http://dx.doi.org/10.1016/j.cbi.2018.06.001] [PMID: 29879413]
[78]
Satpathy S, Patra A, Hussain MD, Kazi M, Aldughaim MS, Ahirwar B. A fraction of Pueraria tuberosa extract, rich in antioxidant compounds, alleviates ovariectomized-induced osteoporosis in rats and inhibits growth of breast and ovarian cancer cells. PLoS One 2021; 16(1): e0240068.
[http://dx.doi.org/10.1371/journal.pone.0240068] [PMID: 33444328]
[79]
Lee OH, Seo DH, Park CS, Kim YC. Puerarin enhances adipocyte differentiation, adiponectin expression, and antioxidant response in 3T3-L1 cells. Biofactors 2010; 36(6): 459-67.
[http://dx.doi.org/10.1002/biof.119] [PMID: 20806284]
[80]
Wu K, Liang T, Duan X, Xu L, Zhang K, Li R. Anti-diabetic effects of puerarin, isolated from Pueraria lobata (Willd.), on streptozotocin-diabetogenic mice through promoting insulin expression and ameliorating metabolic function. Food Chem Toxicol 2013; 60: 341-7.
[http://dx.doi.org/10.1016/j.fct.2013.07.077] [PMID: 23927877]
[81]
Hwang YP, Jeong HG. Mechanism of phytoestrogen puerarin-mediated cytoprotection following oxidative injury: Estrogen receptor-dependent up-regulation of PI3K/Akt and HO-1. Toxicol Appl Pharmacol 2008; 233(3): 371-81.
[http://dx.doi.org/10.1016/j.taap.2008.09.006] [PMID: 18845176]
[82]
Xia DZ, Zhang PH, Fu Y, Yu WF, Ju MT. Hepatoprotective activity of puerarin against carbon tetrachloride-induced injuries in rats: A randomized controlled trial. Food Chem Toxicol 2013; 59: 90-5.
[http://dx.doi.org/10.1016/j.fct.2013.05.055] [PMID: 23764356]
[83]
Xu X, Hu Y, Ruan Q. Effects of puerarin on learning-memory and amino acid transmitters of brain in ovariectomized mice. Planta Med 2004; 70(7): 627-31.
[http://dx.doi.org/10.1055/s-2004-827185] [PMID: 15303253]
[84]
Overstreet DH, Kralic JE, Morrow AL, Ma ZZ, Zhang YW, Lee DYW. NPI-031G (puerarin) reduces anxiogenic effects of alcohol withdrawal or benzodiazepine inverse or 5-HT2C agonists. Pharmacol Biochem Behav 2003; 75(3): 619-25.
[http://dx.doi.org/10.1016/S0091-3057(03)00114-X] [PMID: 12895679]
[85]
Chang Y, Hsieh CY, Peng ZA, et al. Neuroprotective mechanisms of puerarin in middle cerebral artery occlusion-induced brain infarction in rats. J Biomed Sci 2009; 16(1): 9.
[http://dx.doi.org/10.1186/1423-0127-16-9] [PMID: 19272172]
[86]
Xing G, Dong M, Li X, et al. Neuroprotective effects of puerarin against beta-amyloid-induced neurotoxicity in PC12 cells via a PI3K-dependent signaling pathway. Brain Res Bull 2011; 85(3-4): 212-8.
[http://dx.doi.org/10.1016/j.brainresbull.2011.03.024] [PMID: 21473901]
[87]
Tian F, Xu LH, Zhao W, Tian LJ, Ji XL. The neuroprotective mechanism of puerarin treatment of acute spinal cord injury in rats. Neurosci Lett 2013; 543: 64-8.
[http://dx.doi.org/10.1016/j.neulet.2013.03.039] [PMID: 23570727]
[88]
Gao Q, Yang B, Ye Z, Wang J, Bruce IC, Xia Q. Opening the calcium-activated potassium channel participates in the cardioprotective effect of puerarin. Eur J Pharmacol 2007; 574(2-3): 179-84.
[http://dx.doi.org/10.1016/j.ejphar.2007.07.018] [PMID: 17692311]
[89]
Sun XH, Ding JP, Li H, et al. Activation of large-conductance calcium-activated potassium channels by puerarin: The underlying mechanism of puerarin-mediated vasodilation. J Pharmacol Exp Ther 2007; 323(1): 391-7.
[http://dx.doi.org/10.1124/jpet.107.125567] [PMID: 17652634]
[90]
Wang JW, Gao JM, Huang YJ. Effects of puerarin on the vascular active factor related to cerebral vasospasm after aneurysm subarachnoid hemorrhage. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih 2012; 32(2): 164-7.
[PMID: 22574584]
[91]
Saha P, Saraswat G, Chakraborty P, Banerjee S, Pal BC, Kabir SN. Puerarin, a selective oestrogen receptor modulator, disrupts pregnancy in rats at pre-implantation stage. Reproduction 2012; 144(5): 633-45.
[http://dx.doi.org/10.1530/REP-11-0423] [PMID: 22919047]
[92]
Liu CM, Ma JQ, Sun YZ. Puerarin protects rat kidney from lead-induced apoptosis by modulating the PI3K/Akt/eNOS pathway. Toxicol Appl Pharmacol 2012; 258(3): 330-42.
[http://dx.doi.org/10.1016/j.taap.2011.11.015] [PMID: 22172631]
[93]
Cheng YF, Zhu GQ, Wang M, et al. Involvement of ubiquitin proteasome system in protective mechanisms of Puerarin to MPP+-elicited apoptosis. Neurosci Res 2009; 63(1): 52-8.
[http://dx.doi.org/10.1016/j.neures.2008.10.009] [PMID: 19022306]
[94]
Zhu G, Wang X, Wu S, Li Q. Involvement of activation of PI3K/Akt pathway in the protective effects of puerarin against MPP+-induced human neuroblastoma SH-SY5Y cell death. Neurochem Int 2012; 60(4): 400-8.
[http://dx.doi.org/10.1016/j.neuint.2012.01.003] [PMID: 22265823]
[95]
Zhu G, Wang X, Chen Y, et al. Puerarin protects dopaminergic neurons against 6-hydroxydopamine neurotoxicity via inhibiting apoptosis and upregulating glial cell line-derived neurotrophic factor in a rat model of Parkinson’s disease. Planta Med 2010; 76(16): 1820-6.
[http://dx.doi.org/10.1055/s-0030-1249976] [PMID: 20509103]
[96]
Malaivijitnond S, Tungmunnithum D, Gittarasanee S, Kawin K, Limjunyawong N. Puerarin exhibits weak estrogenic activity in female rats. Fitoterapia 2010; 81(6): 569-76.
[http://dx.doi.org/10.1016/j.fitote.2010.01.019] [PMID: 20117180]
[97]
Rani VU, Sudhakar M, Ramesh A. Protective effect of Pueraria tuberosa Linn. in arsenic induced nephrotoxicity in rats. Asian Journal of Pharmaceutical Research 2017; 7(1): 15-20.
[http://dx.doi.org/10.5958/2231-5691.2017.00003.X]
[98]
Chueh FS, Chang CP, Chio CC, Lin MT. Puerarin acts through brain serotonergic mechanisms to induce thermal effects. J Pharmacol Sci 2004; 96(4): 420-7.
[http://dx.doi.org/10.1254/jphs.FP0040424] [PMID: 15599109]
[99]
Pramanik SS, Sur T, Debnath P, Pramanik T, Bhattacharyya D. Effect of Pueraria tuberosa on cold immobilization stress induced changes in plasma corticosterone and brain monoamines in rats. J Nat Rem 2011; 11(1): 69-75.
[100]
Jin XL, Zhu XY. Pharmacokinetics of puerarin in rats, rabbits, and dogs. Chung Kuo Yao Li Hsueh Pao 1992; 13(3): 284-8.
[PMID: 1442117]
[101]
Yang R, Wang Q, Zeng H, Qin Z, Li J, Qu L. Determination of puerarin in biological samples and its application to a pharmacokinetic study by flow-injection chemiluminescence. Luminescence 2011; 26(5): 368-73.
[http://dx.doi.org/10.1002/bio.1281] [PMID: 21547999]
[102]
Ouyang Z, Zhao M, Tang J, Pan L. In vivo pharmacokinetic comparisons of ferulic acid and puerarin after oral administration of monomer, medicinal substance aqueous extract and Nao-De-Sheng to rats. Pharmacogn Mag 2012; 8(32): 256-62.
[http://dx.doi.org/10.4103/0973-1296.103648] [PMID: 24082627]
[103]
Anukunwithaya T, Poo P, Hunsakunachai N, Rodsiri R, Malaivijitnond S, Khemawoot P. Absolute oral bioavailability and disposition kinetics of puerarin in female rats. BMC Pharmacol Toxicol 2018; 19(1): 25.
[http://dx.doi.org/10.1186/s40360-018-0216-3] [PMID: 29801513]
[104]
Kong H, Wang X, Shi R, et al. Pharmacokinetics and tissue distribution kinetics of puerarin in rats using indirect competitive ELISA. Molecules 2017; 22(6): 939.
[http://dx.doi.org/10.3390/molecules22060939] [PMID: 28587251]
[105]
Prasain JK, Peng N, Moore R, Arabshahi A, Barnes S, Wyss JM. Tissue distribution of puerarin and its conjugated metabolites in rats assessed by liquid chromatography-tandem mass spectrometry. Phytomedicine 2009; 16(1): 65-71.
[http://dx.doi.org/10.1016/j.phymed.2008.09.004] [PMID: 19027277]
[106]
Cao L, Pu J, Cao QR, Chen BW, Lee BJ, Cui JH. Pharmacokinetics of puerarin in pregnant rats at different stages of gestation after oral administration. Fitoterapia 2013; 86(86): 202-7.
[http://dx.doi.org/10.1016/j.fitote.2013.03.004] [PMID: 23500385]
[107]
Prasain JK, Jones K, Brissie N, Moore R, Wyss JM, Barnes S. Identification of puerarin and its metabolites in rats by liquid chromatography-tandem mass spectrometry. J Agric Food Chem 2004; 52(12): 3708-12.
[http://dx.doi.org/10.1021/jf040037t] [PMID: 15186086]
[108]
Wen B-Y, Li H, Wang L, Wang SC. Metabolic kinetic of puerarin in beagle liver microsomal by HPLC-ESI-MS. Zhongguo Zhongyao Zazhi 2008; 33(23): 2834-7.
[PMID: 19260325]
[109]
Jung HR, Kim SJ, Ham SH, Cho JH, Lee YB, Cho HY. Simultaneous determination of puerarin and its active metabolite in human plasma by UPLC-MS/MS: Application to a pharmacokinetic study. J Chromatogr B Analyt Technol Biomed Life Sci 2014; 971(971): 64-71.
[http://dx.doi.org/10.1016/j.jchromb.2014.09.015] [PMID: 25264914]
[110]
Yasuda T, Kano Y, Saito K, Ohsawa K. Urinary and biliary metabolites of puerarin in rats. Biol Pharm Bull 1995; 18(2): 300-3.
[http://dx.doi.org/10.1248/bpb.18.300] [PMID: 7742802]
[111]
Luo CF, Cai B, Hou N, et al. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for puerarin metabolism in human liver microsomes. Arch Toxicol 2012; 86(11): 1681-90.
[http://dx.doi.org/10.1007/s00204-012-0874-7] [PMID: 22648071]
[112]
Zhang YC, Huang LP. The observation of clinical efficacy of puerarin glucose injection therapy in 30 cases with brain infarction. J Jinggangshan Uni 2006; 5: 94-5.
[113]
Jiang GH. The observation of efficacy of puerarin glucose injection therapy with brain infarction (Chinese). J Youjiang Med Coll Nationalities 2006; 13: 900.
[114]
Lu JM, Lu YZ. The observation of efficacy of puerarin in 58 cases with acute cerebral infarction (Chinese). Zhongguo Laonianxue Zazhi 2011; 13: 2575-6.
[115]
Xu P, Zhou YF. The observation of efficacy of puerarin with acute cerebral infarction (Chinese). China J Clin Rational Drug Use 2011; 20: 58-9.
[116]
Guo ZF. The observation of efficacy of puerarin injection in 45 cases with acute cerebral infarction (Chinese). Public Med Forum Magazine 2007; 8: 310-1.
[117]
Bi SQ, Li GQ, Zhou HG, et al. The observation of efficacy of puerarin in 50 cases with acute cerebral infarction (Chinese). Chin J Pract Nerv Dis 2007; 3: 117-8.
[118]
Li JW. The clinical study of puerarin injection with acute cerebral infarction (Chinese). Strait Pharm J 2013; 4: 67-9.
[119]
Cao Z. Clinical observation of puerarin injection with acute cerebral infarction (Chinese). J Med Forum 2010; 3: 85-6.
[120]
Deng JG. Curative effects and adverse reactions of treating cerebral infarction with puerarin injection (Chinese). Anhui Health Vocational Tech Coll 2010; 3: 57-8.
[121]
Zhang JX, Li ZG. Clinical observation on the treatment of acute cerebral infarction by Puerarin in 30 cases (Chinese). Acta Academiae Medicinae 2001; 10: 25-6.
[122]
Santosh N, Mohan K, Royana S, Yamini TB. Hepatotoxicity of tubers of Indian Kudzu (Pueraria tuberosa) in rats. Food Chem Toxicol 2010; 48(4): 1066-71.
[http://dx.doi.org/10.1016/j.fct.2010.01.026] [PMID: 20122980]
[123]
Jifen Z. Puerarin freeze-dried Pickering emulsion and preparation method thereof. C.N. Patent 110151696B2020.,
[124]
Jianfang F, Liangxing T, Kaili H, Lei X, Yan Z. Puerarin nano crystal capsule and preparation method thereof. C.N. Patent 105982877B2021.,
[125]
Yindi Z, Yanqin Z, Jianping S, et al. Puerarin gel eyedrop is preparing the application in treating retinopathy medicine. C.N. Patent 104688672B2018.,
[126]
Zhuan F, Wei Z, Jingjiang W, Yao W, Long B, Dongming CZ. The method for isolating and purifying Puerarin (Pueraria lobota). C.N. Patent105017235B2017.,
[127]
Dajian Y, Yueming L, Shilin C, Xinzi C. Puerarin derivate and medical usage thereof. C.N. Patent 100572374C2009.,
[128]
Xuansheng D, Xiaodong C, Sheng Y, Haidong X, Cigang Y, Yun Z. Glycosyl-derivatives of puerarin, pharmaceutical compositon, preparation method and use thereof. W.O. Patent 2010045755A12010.,
[129]
Sheng Y, Xiaodong C, Xuan D, Haidong X, Cigang Y, Yun Z. Puerarin glycosylation derivative, medicine compound, preparation method and application thereof. C.N. Patent 101723997A2010.,
[130]
Hongxiang L, Guangxi Z, Longru S. Puerarin oral preparation and its preparation method. C.N. Patent 1205941C2005.,
[131]
Ziren S, Jiannan C, Xiaoping L. Use of taurine in preparation of injection containing Puerarin. C.N. Patent 100435803C2008.,
[132]
Bingfang H, Xue Y, Chu M, et al. Fructosylated puerarin and its preparation and use. J.P. Patent 671622B22015.,
[133]
Liu L. Puerarin hydrates, preparation methods and uses thereof. U.S. Patent 20130331345A12013.,
[134]
Aiping Z, Xiaoyan Z, Jianxu S, Lisha W. Puerarin nanocrystalline medical composition and preparation method thereof. C.N. Patent 103211759B2015.,
[135]
Sharma KA. Herbal composition for treatment of hypertension and associated disorders. W. O. Patent 2015068112A32015.,